A 16-year-old patient with Charcot Marie Tooth disease in variant c.217G>C of the INF2 gene and focal glomerulosclerosis – a case report
暂无分享,去创建一个
R. Płoski | M. Rydzanicz | D. Aebisher | J. Kosińska | A. Pyrkosz | Marian Przygoda | Dawid Matias | Maciej Jurczak | Aldona Sokołowska | Karolina Raba | Juliusz Wołkanowski
[1] A. Ortega-Yago,et al. Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results. , 2021, Revista espanola de cirugia ortopedica y traumatologia.
[2] P. Aubourg,et al. AAV2/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A , 2021, Nature Communications.
[3] M. M. López-Rodríguez,et al. Metabolic and Functional Improvements in a Patient with Charcot-Marie-Tooth Disease Type 2 after EGCG Administration: A Case Report , 2021, Medicina.
[4] U. Manor,et al. Impaired Mitochondrial Mobility in Charcot-Marie-Tooth Disease , 2020, Frontiers in Cell and Developmental Biology.
[5] M. A. Alonso,et al. The formin INF2 in disease: progress from 10 years of research , 2020, Cellular and Molecular Life Sciences.
[6] Anirudh Gupta,et al. Charcot-Marie-Tooth: From Molecules to Therapy , 2019, International journal of molecular sciences.
[7] M. Fontès. Charcot Marie Tooth Disease. A Single Disorder? , 2018, International journal of molecular sciences.
[8] C. Pupe,et al. Pain in Charcot-Marie-Tooth disease: an update , 2017, Arquivos de Neuro-Psiquiatria.
[9] A. Baron,et al. Maladie de Charcot-Marie-Tooth - Éléments de rééducation fonctionnelle, kinésithérapie, ergothérapie , 2017 .
[10] K. Refshauge,et al. Safety and efficacy of progressive resistance exercise for Charcot-Marie-Tooth disease in children: a randomised, double-blind, sham-controlled trial. , 2017, The Lancet. Child & adolescent health.
[11] E. Gallardo,et al. Intermediate Charcot–Marie–Tooth disease: an electrophysiological reappraisal and systematic review , 2017, Journal of Neurology.
[12] E. Dimitrova,et al. The Role of Rehabilitation in the Management of Patients with Charcot-Marie-Tooth Disease: Report of Two Cases , 2016, Open access Macedonian journal of medical sciences.
[13] B. Corrado,et al. Rehabilitation Management of the Charcot–Marie–Tooth Syndrome , 2016, Medicine.
[14] P. Nunes,et al. Epidemiologic Study of Charcot-Marie-Tooth Disease: A Systematic Review , 2016, Neuroepidemiology.
[15] Kota Watanabe. [Treatment for Patients with Charcot-Marie-Tooth Disease: Orthopaedic Aspects]. , 2016, Brain and nerve = Shinkei kenkyu no shinpo.
[16] T. Boffeli,et al. Minimally Invasive Early Operative Treatment of Progressive Foot and Ankle Deformity Associated With Charcot-Marie-Tooth Disease. , 2015, The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons.
[17] Ruxu Zhang,et al. Intermediate Charcot-Marie-Tooth disease , 2014, Neuroscience Bulletin.
[18] D. Radice,et al. Pain and small fiber function in charcot–marie–tooth disease type 1A , 2014, Muscle & nerve.
[19] G. Braathen. Genetic epidemiology of Charcot–Marie–Tooth disease , 2012, Acta neurologica Scandinavica. Supplementum.
[20] G. Mollet,et al. INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy. , 2011, The New England journal of medicine.
[21] F. Kok,et al. Clinical and neurophysiological investigation of a large family with dominant Charcot-Marie-Tooth type 2 disease with pyramidal signs. , 2011, Arquivos de neuro-psiquiatria.
[22] T. Pollard,et al. Review of the mechanism of processive actin filament elongation by formins. , 2009, Cell motility and the cytoskeleton.
[23] Davide Pareyson,et al. Diagnosis, natural history, and management of Charcot–Marie–Tooth disease , 2009, The Lancet Neurology.
[24] B. Goode,et al. Actin nucleation and elongation factors: mechanisms and interplay. , 2009, Current opinion in cell biology.
[25] J. Lupski,et al. MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. , 2006, Brain : a journal of neurology.
[26] F. Baas,et al. Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2 , 2006, Annals of neurology.
[27] M. Fontès,et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease , 2004, Nature Medicine.
[28] D. Pellman,et al. A conserved mechanism for Bni1- and mDia1-induced actin assembly and dual regulation of Bni1 by Bud6 and profilin. , 2003, Molecular biology of the cell.
[29] V. E. Wood,et al. Treatment of the Upper Limb in Charcot–Marie–Tooth Disease , 1995, Journal of hand surgery.
[30] P K Thomas,et al. The clinical features of hereditary motor and sensory neuropathy types I and II. , 1980, Brain : a journal of neurology.